NCT05835635View on ClinicalTrials.gov

Switch From Oral Therapy to Long-acting Injectable Cabotegravir + Rilpivirine

Not yet recruitingOBSERVATIONAL

Enrollment

50

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

December 1, 2025

Study Completion Date

May 1, 2026

Conditions

Patient SatisfactionPatient PreferenceQuality of LifeAcceptability of Health Care

Trial Locations (1)

3830000

CICUC, Santiago

Sponsors

Collaborators (1)

ViiV Healthcare

All Listed Sponsors

collaborator

ViiV Healthcare

INDUSTRY

lead

Pontificia Universidad Catolica de Chile

OTHER

NCT05835635 - Switch From Oral Therapy to Long-acting Injectable Cabotegravir + Rilpivirine | Biotech Hunter | Biotech Hunter